FOXO Technologies Inc. Regains Compliance with NYSE American Listing Standards

FOXO Technologies Inc. (NYSEAMERICAN: FOXO) has recently announced that it has successfully resolved its listing deficiency with NYSE American LLC. On December 16, 2024, the company received a letter from NYSE Regulation stating that it is now in compliance with all the NYSE American LLC continued listing standards outlined in Part 10 of the NYSE American Company Guide.

Specifically, the letter addressed the company’s compliance with Sections 1003(a)(i) and (ii) of the Company Guide, which were previously highlighted in letters from the Exchange dated June 12, 2023, and July 10, 2024.

While FOXO Technologies Inc. will be subject to NYSE Regulation’s standard continued listing monitoring, the company must remain vigilant. According to Section 1009(h) of the Company Guide, failure to uphold listing standards within 12 months of this notification may prompt NYSE American to reevaluate the company’s approach to financial recovery. Depending on the circumstances, this could lead to expedited compliance measures or immediate delisting proceedings.

Effective December 17, 2024, the “.BC” indicator will cease to be disseminated, signifying the company’s removal from the list of NYSE American noncompliant issuers on the Exchange’s website.

FOXO Technologies Inc. assured stakeholders that it is committed to maintaining compliance with all relevant regulations. The company’s CEO, Seamus Lagan, signed off on the report, affirming FOXO’s dedication to meeting and exceeding listing standards.

This development marks a positive turn for FOXO Technologies Inc. as it demonstrates the company’s commitment to upholding the highest standards of governance and compliance within the NYSE American framework.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read FOXO Technologies’s 8K filing here.

About FOXO Technologies

FOXO Technologies Inc engages in epigenetic biomarker underwriting technology and consumer engagement platform service business in the United States. It operates through two segments, FOXO Labs and FOXO Life. The company applies automated machine learning and artificial intelligence technologies to discover epigenetic biomarkers of human health, wellness, and aging.